Eligard four-month formulation
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Atrix/Sanofi-Synthelabo's prostate cancer therapy Eligard (leuprolide acetate for injectable suspension) is approved Feb. 13 in a 30 mg, four-month formulation. The hormone therapy was previously approved in 7.5 mg (one-month) and 22.5 mg (three-month) formulations. Studies in additional formulations are underwa
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.